1. Home
  2. ECPG vs IVA Comparison

ECPG vs IVA Comparison

Compare ECPG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECPG
  • IVA
  • Stock Information
  • Founded
  • ECPG 1998
  • IVA 2011
  • Country
  • ECPG United States
  • IVA France
  • Employees
  • ECPG N/A
  • IVA N/A
  • Industry
  • ECPG Finance Companies
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECPG Finance
  • IVA Health Care
  • Exchange
  • ECPG Nasdaq
  • IVA Nasdaq
  • Market Cap
  • ECPG 905.2M
  • IVA 769.0M
  • IPO Year
  • ECPG 1999
  • IVA 2020
  • Fundamental
  • Price
  • ECPG $44.65
  • IVA $5.28
  • Analyst Decision
  • ECPG Strong Buy
  • IVA Strong Buy
  • Analyst Count
  • ECPG 3
  • IVA 6
  • Target Price
  • ECPG $62.67
  • IVA $15.33
  • AVG Volume (30 Days)
  • ECPG 308.9K
  • IVA 74.0K
  • Earning Date
  • ECPG 11-05-2025
  • IVA 09-26-2025
  • Dividend Yield
  • ECPG N/A
  • IVA N/A
  • EPS Growth
  • ECPG N/A
  • IVA N/A
  • EPS
  • ECPG N/A
  • IVA N/A
  • Revenue
  • ECPG $1,467,587,000.00
  • IVA $14,591,573.00
  • Revenue This Year
  • ECPG $27.55
  • IVA $80.35
  • Revenue Next Year
  • ECPG $5.84
  • IVA N/A
  • P/E Ratio
  • ECPG N/A
  • IVA N/A
  • Revenue Growth
  • ECPG 15.50
  • IVA N/A
  • 52 Week Low
  • ECPG $26.45
  • IVA $1.53
  • 52 Week High
  • ECPG $51.77
  • IVA $6.50
  • Technical
  • Relative Strength Index (RSI)
  • ECPG 64.26
  • IVA 54.95
  • Support Level
  • ECPG $43.02
  • IVA $5.21
  • Resistance Level
  • ECPG $45.29
  • IVA $5.78
  • Average True Range (ATR)
  • ECPG 1.20
  • IVA 0.37
  • MACD
  • ECPG 0.10
  • IVA -0.09
  • Stochastic Oscillator
  • ECPG 69.52
  • IVA 9.56

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: